PetMed Express (NASDAQ:PETS) Cut to “Hold” at StockNews.com

StockNews.com lowered shares of PetMed Express (NASDAQ:PETS) from a buy rating to a hold rating in a report issued on Tuesday.

PetMed Express Trading Up 8.2 %

Shares of NASDAQ PETS opened at $4.47 on Tuesday. The company has a market cap of $92.35 million, a price-to-earnings ratio of -74.50 and a beta of 0.70. PetMed Express has a 12 month low of $2.90 and a 12 month high of $6.85. The stock has a 50-day moving average price of $5.11 and a two-hundred day moving average price of $4.32.

PetMed Express (NASDAQ:PETS) last issued its earnings results on Monday, February 10th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.02). PetMed Express had a negative return on equity of 1.00% and a negative net margin of 0.37%. On average, sell-side analysts predict that PetMed Express will post 0.24 earnings per share for the current year.

Insider Activity at PetMed Express

In other PetMed Express news, Director Leslie C.G. Campbell purchased 15,000 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were purchased at an average cost of $5.38 per share, for a total transaction of $80,700.00. Following the acquisition, the director now owns 70,000 shares of the company’s stock, valued at approximately $376,600. This represents a 27.27 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On PetMed Express

A number of institutional investors and hedge funds have recently modified their holdings of the business. Arrowstreet Capital Limited Partnership boosted its holdings in shares of PetMed Express by 26.5% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 513,381 shares of the company’s stock worth $2,474,000 after buying an additional 107,614 shares in the last quarter. Geode Capital Management LLC increased its position in shares of PetMed Express by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 224,788 shares of the company’s stock valued at $1,084,000 after purchasing an additional 3,558 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of PetMed Express by 355.5% during the 4th quarter. JPMorgan Chase & Co. now owns 106,954 shares of the company’s stock valued at $516,000 after purchasing an additional 83,473 shares during the last quarter. Bleakley Financial Group LLC purchased a new stake in shares of PetMed Express during the 3rd quarter valued at $279,000. Finally, American Century Companies Inc. increased its position in shares of PetMed Express by 15.3% during the 4th quarter. American Century Companies Inc. now owns 33,662 shares of the company’s stock valued at $162,000 after purchasing an additional 4,459 shares during the last quarter. 73.33% of the stock is currently owned by institutional investors.

PetMed Express Company Profile

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.